– Expands intellectual property portfolio and strengthens position as leading innovator in developing putative psychedelic compounds – TORONTO–( BUSINESS WIRE)–Cybin Inc. ( NEO:CYBN) ( NYSE American:CYBN) (“ Cybin” or the “ Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM” today announced that it has been awarded a Notice of Allowance from the U.S.


Previous articleEditor’s Choice Award 2021-Best Study on Psychedelics and Neuroplasticity
Next articleAwakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights